A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Eli Lilly and Company.

Editor’s Note: This article was updated on a continuous basis for news announced from Wednesday February 21, 2018 date to Tuesday February 27, 2018.

FDA OKs New Use for Lilly’s Cancer Drug Verzenio
The US Food and Drug Administration (FDA) has approved Eli Lilly and Company’s Verzenio (abemaciclib), a breast cancer drug, in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for treating post-menopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.

This additional FDA approval marks the third indication for Verzenio within five months. In September 2017, Verzenio was approved in combination and as a single agent in metastatic breast cancer. Specifically, Verzenio was approved for use in combination with fulvestrant for treating women with HR+, HER2- advanced or metastatic breast cancer with disease progression following endocrine therapy, and as monotherapy for treating adult patients with HR+, HER2- advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

Source: Eli Lilly and Company